Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer [5]

Cancer

Volumn 110, Issue 2, 2007, Pages 469-470

  Ural, Ali U ^a   Avcu, Ferit ^a   Baran, Yusuf ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; RADIOSENSITIZING AGENT; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CORONARY ARTERY DISEASE; DISEASE FREE SURVIVAL; HEART INFARCTION; HUMAN; LETTER; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CORONARY ARTERIOSCLEROSIS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 34547148070     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22804     Document Type: Letter

References (3)

1. Jagsi R, Griffith KA, Koelling T, et al. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109:650-657.
2. Avcu F, Ural AU, Yilmaz MI, et al. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane. Eur J Haematol. 2005;74:496-500.
3. Ural AU, Avcu F, Candir M, et al. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res. 2006;8:R52 [Epub ahead of print].